Tetratriacontanal | 132912-09-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Tetratriacontanal
• CAS: 132912-09-5
• 化学式: C₃₄H₆₈O
• 分子量: 492.9
• InChiKey: ZSRZISBVEUGQRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.8
• 重原子数：
  35
• 可旋转键数：
  32
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Methylene Blue Derivatives
  申请人：Rariy V. Roman

  公开号：US20070116757A1

  公开（公告）日：2007-05-24

  Pharmaceutical compositions comprising a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfate salt, an aryl sulfate salt or an alkyl aryl sulfonate salt of methylene blue or a derivative of methylene blue are described herein. The compositions are preferably administered orally and can be administered as tablets, soft or hard shell capsules (e.g. soft gelatin capsules), suspensions or solutions. The composition can also be formulated as a suppository or enema or rectal administration. The compositions further comprise a pharmaceutically acceptable carrier and optionally one or more pharmaceutically acceptable excipients. Suitable excipients include diluents, binders, plasticizers, lubricants, disintegrants, colorants, stabilizers, surfactants, and combinations thereof. The fatty acid salts, alkyl sulate salts, aryl sulfate salts or alkyl aryl sulfonate salts can be co-mixed or co-melted with one or more fatty acids to make more hydrophobic compositions, which may result in less staining formulations. The compositions can be formulated for immediate release, controlled release such as extended release, delayed release, and pulsatile release, or combinations thereof. In one embodiment, the derivative of methylene blue is methylene dodecylsulfate.

  本文描述了包含脂肪酸盐、二羧酸盐、烷基硫酸盐、芳基硫酸盐或烷基芳基磺酸盐的甲蓝或甲蓝衍生物的制药组合物。这些组合物最好是口服给药，可以制成片剂、软壳或硬壳胶囊（例如软明胶胶囊）、悬浮液或溶液进行给药。该组合物也可以制成栓剂或灌肠剂或直肠给药。这些组合物还包括一种药用可接受载体，以及可选地一种或多种药用可接受的辅料。适用的辅料包括稀释剂、粘结剂、增塑剂、润滑剂、崩解剂、色素、稳定剂、表面活性剂以及它们的组合。脂肪酸盐、烷基硫酸盐、芳基硫酸盐或烷基芳基磺酸盐可以与一种或多种脂肪酸共混或共熔，制成更疏水的组合物，这可能导致更少的染色配方。这些组合物可以制成即时释放、控制释放（如延长释放）、延迟释放和脉冲释放，或者以上述的组合形式。在一个实施例中，甲蓝的衍生物是十二烷基硫酸甲蓝。
• Methods for ameliorating icthyosiform skin diseases
  申请人：——

  公开号：US20030072795A1

  公开（公告）日：2003-04-17

  The present invention relates to the discovery of a method to provide stabilized transglutaminase 1 enzyme, involucrin, and other molecules necessary for the assembly of the cell envelope to skin cells. Novel biological tools, prophylactics, therapeutics, cosmetics, and methods of use of the foregoing for study, prevention, and treatment of skin disorders are also disclosed.

  本发明涉及发现一种方法，以提供稳定的转谷氨酰胺酶1酶，包裹蛋白和其他必要分子以组装细胞外壳到皮肤细胞上。还公开了新的生物工具、预防药、治疗药、化妆品以及上述用于研究、预防和治疗皮肤疾病的使用方法。
• Vesicles and polymeric vesicles
  申请人：Kao Corporation

  公开号：EP0503508A1

  公开（公告）日：1992-09-16

  A vesicle comprising, as a membrane-forming ingredient, a phosphoric ester represented by the following general formula (2): wherein R¹ means a hydrogen atom or an alkyl group having 1-4 carbon atoms, R² denotes an alkylene group having 1-6 carbon atoms, R³ and R⁴ may be identical to or different from each other and represent individually an alkyl group having 1-4 carbon atoms, R⁵ stands for an alkylene group having 2-3 carbon atoms, R⁶ means a linear or branched alkyl or alkenyl group which may be substituted by halogen atoms and has 8-36 carbon atoms, a phenyl group which has been substituted by a linear or branched alkyl group having 3-15 carbon atoms or a group represented by the following general formula (3) or (4): in which R⁹ and R¹⁰ may be identical to or different from each other and mean individually a hydrogen atom, a saturated or unsaturated, linear or branched acyl group having 5-36 carbon atoms or a linear or branched alkyl or alkenyl group having 5-36 carbon atoms, provided that both R⁹ and R¹⁰ are not a hydrogen atom at the same time, A denotes NH or an oxygen atom, and n stands for a number of from 0-30, and a polymeric vesicle comprising, as a membrane-forming ingredient, a polymer of the phosphoric ester represented by the general formula (2).

  一种囊泡，其成膜成分是由以下通式（2）代表的磷酸酯： 其中，R¹ 表示氢原子或具有 1-4 个碳原子的烷基，R² 表示具有 1-6 个碳原子的亚烷基，R³ 和 R⁴ 可以彼此相同或不同，并分别代表具有 1-4 个碳原子的烷基，R⁵ 代表具有 2-3 个碳原子的亚烷基、R⁶ 表示可被卤素原子取代且具有 8-36 个碳原子的直链或支链烷基或烯基、被具有 3-15 个碳原子的直链或支链烷基取代的苯基或由以下通式 (3) 或 (4) 代表的基团： 其中 R⁹和 R¹⁰ 可以彼此相同或不同，分别指氢原子、具有 5-36 个碳原子的饱和或不饱和、直链或支链酰基或具有 5-36 个碳原子的直链或支链烷基或烯基、R⁹ 和 R¹⁰ 不能同时为氢原子，A 表示 NH 或氧原子，n 代表 0-30 之间的数字，以及一种聚合囊泡，其中包含通式（2）所代表的磷酸酯聚合物作为成膜成分。
• Derivatives of 6,7-Dihydroxy-4-thiaheptonic acid and their use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0638588A1

  公开（公告）日：1995-02-15

  A compound of the formula: wherein each of R¹ and R² is hydrogen or an aliphatic acyl group, each of R³ and R⁴ is hydrogen or a protecting group, X is an amino acid sequence consisting of 1 to 10 amino acid residues which may be protected, Y is an amino acid sequence consisting of 1 to 5 amino acids residues which may be protected, bounding at a terminal carboxyl group, or a salt thereof has an activity of remarkably improving hematopoietic disorder and is useful as an immuno-stimulating agent or an agent for treating thrombocytopenia.

  式中的化合物： 其中R¹和R²各自为氢或脂肪酰基，R³和R⁴各自为氢或保护基，X为由1至10个可被保护的氨基酸残基组成的氨基酸序列、Y 是由 1 至 5 个氨基酸残基组成的氨基酸序列，可被保护，与末端羧基结合，或其盐具有显著改善造血障碍的活性，可用作免疫刺激剂或治疗血小板减少症的药物。
• WATER-BASED-INK COMPOSITION
  申请人：TOYO INK SC HOLDINGS CO., LTD.

  公开号：EP3366730A1

  公开（公告）日：2018-08-29

  An aqueous ink composition containing, at least, water, a pigment (but excluding titanium oxides in which the pigment surface has been treated with an organic compound), a pigment dispersing resin, and two or more types of alkyl polyols having boiling points of at least 180°C but not more than 250°C at 1 atmosphere, wherein the pigment dispersing resin has an alkyl group of 10 to 36 carbon atoms, and the total amount of the alkyl polyols, relative to the total weight of the aqueous ink composition, is at least 10% by weight but not more than 30% by weight.

  一种水性油墨组合物，至少含有水、颜料（但不包括颜料表面经有机化合物处理的钛氧化物）、颜料分散树脂和两种或两种以上在 1 个大气压下沸点至少为 180℃但不超过 250℃的烷基多元醇、其中颜料分散树脂具有 10 至 36 个碳原子的烷基，烷基多元醇的总量相对于水性墨水组合物的总重量至少为 10%，但不超过 30%。